The COVID-19 health crisis has introduced new dynamics in the global healthcare system while pushing leading pharmaceutical companies into investing more in research and development as others are enticed into mergers...
The initial outbreak of the COVID-19 pandemic delayed merger and acquisitions in the pharma sector, but evidence points to an uptick in activity because the rationale for sealing deals hasn’t changed
The acceleration of consumer trends and behavior that was already underway prior to the COVID-19 outbreak has taken another leap forward and will spark consumer-facing companies and retailers to reinvent the way they do business, according to a new PwC re